Table: Anges - 9-MTH group results
Nov 8 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2022 Sep 30, 2021 Dec 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 45 mln 44 mln
(+3.1 pct) (+56.9 pct)
Operating loss 12.46 loss 12.16
Recurring loss 10.06 loss 11.82
Net loss 10.19 loss 11.95
EPS loss 66.60 yen loss 82.25 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001